Protara Therapeutics
TARA
35 hedge funds and large institutions have $33.2M invested in Protara Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 7 closing their positions.
233% more call options, than puts
Call options by funds: $20K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.45% less ownership
Funds ownership: 61.2% → 57.74% (-3.5%)
10% less funds holding
Funds holding: 39 → 35 (-4)
30% less capital invested
Capital invested by funds: $47.1M → $33.2M (-$13.9M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$230K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$126K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$90.3K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$55.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$598K |
| 2 |
Two Sigma Advisers
New York
|
-$552K |
| 3 |
Two Sigma Investments
New York
|
-$534K |
| 4 |
Goldman Sachs
New York
|
-$234K |
| 5 |
PA
Perceptive Advisors
New York
|
-$200K |
TARA Hedge Fund Activity: Q1 2022 in Review
35 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2022, worth a combined $33.2M — down 30% from $47.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TARA and 3 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $230K. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $598K sold.
- 35 institutional investors held Protara Therapeutics (TARA) as of Q1 2022, down from 39 in Q4 2021.
- Funds reported $33.2M of Protara Therapeutics stock for Q1 2022, down 30% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest Protara Therapeutics buyer in Q1 2022 was Assenagon Asset Management, an estimated $230K added.
- The largest Protara Therapeutics seller in Q1 2022 was Financial Advocates Investment Management, an estimated $598K sold.
Based on aggregated 13F filings for Q1 2022.